ClinicalTrials.gg
Active, not recruitingNCT02935400Updated May 12, 2026

Acute Porphyria Biomarkers for Disease Activity

An observational study in Acute Intermittent Porphyria, Hereditary Coproporphyria and Variegate Porphyria, sponsored by The University of Texas Medical Branch, Galveston. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by The University of Texas Medical Branch, Galveston · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.

Started
2014
with 1 other
Observational
6 of 12
2 open now
Registered
7th of 12
by date
Lead sponsor
3 of 12
The University of Texas Medical Branch, Galveston

Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is one of 2 that started in 2014, is one of 6 observational ones, and was the 7th registered.

Porphyria, Acute Intermittent

21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.

Browse Porphyria, Acute Intermittent studies →

Open to participants now

2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Porphyria, Acute Intermittent with a site in United States, or all of them as a file.
02

Study summary

The long term objective of the research is to identify new biomarkers of disease activity in the human acute porphyrias. This pilot study is intended to provide pilot and feasibility data needed to plan larger and more definitive future studies.

Read the detailed description

This translational pilot research is based on preliminary results using animal models. The investigators will collect samples of blood, urine and feces from up to 50 participants with well documented acute porphyrias, at 2 expert sites that are members of the Porphyrias Consortium. Collection and analysis of these samples will be used to assess feasibility of performing such studies in humans with acute porphyrias, recognizing that these disorders are more heterogeneous than reproduced in animal models, and affect individuals who cannot all be studied simultaneously and in large groups. Therefore, we will assess the feasibility of methods for collecting, processing, storing and shipping samples at multiple study sites for later biomarker analysis. Larger and more definitive studies of biomarkers will be designed and implemented based on data and experience from this pilot-feasibility study.

03

Conditions studied

  • Acute Intermittent Porphyria
  • Hereditary Coproporphyria
  • Variegate Porphyria

Keywords

  • porphyria
  • biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Acute intermittent porphyria, hereditary coproporphyria, variegate porphyria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of acute porphyria.

    1. For AIP: Elevation in urine PBG, with normal or only slight increases in plasma and fecal porphyrins. Most (\~90%) will have deficient activity of erythrocyte PBGD.
    2. For HCP: Elevation in urine PBG, with substantial increases in fecal porphyrins (almost entirely coproporphyrin III). In the absence of skin photosensitivity, most will have normal or only slight increases in plasma porphyrins.
    3. For VP: Elevation in PBG, with substantial increases in fecal porphyrins (mostly coproporphyrin III and protoporphyrin), increased plasma total porphyrins and a fluorescence emission maximum of diluted plasma at neutral pH near 626 nm.

Exclusion criteria

Exclusion Criteria:

  • Another medical condition that might confound the results, as judged by the investigator
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Asymptomatic

    Group 1 will have had no symptoms of porphyria in the past year.

  • Symptomatic and treated with hemin

    Group 2 will have a history of symptoms within the past year.

    Drug: Hemin

Interventions

  • DrugHemin

    Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.

    Also known as: Panhematin

06

What researchers measure

Primary outcomes

  1. Potential biomarkers Biomarkers

    Expression of heme biosynthetic and heat and stress response genes

    Time frame: 10 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Data not entered

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2014 (actual). Primary completion is estimated for Dec 2026, 152 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2016
First posted
Oct 17, 2016
StartActual
Apr 28, 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 31, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02935400
Responsible party
Sponsor
First posted
Oct 17, 2016
Start date
Apr 28, 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 12, 2026

Study contacts

Karl E Anderson
principal investigator · University of Texas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion